chemotherapy

Patrick DalyLung Cancer | September 21, 2023

In a recent meta-analysis, Xin Tao and colleagues examined the capability of omega-3 polyunsaturated fatty acids (PUFAs) ...

Patrick DalySmall Cell Lung Cancer | September 21, 2023

Patients with extensive-stage small cell lung cancer (ES-SCLC) continue to face poor survival outcomes. Consolidative ...

Rob DillardLung Cancer | September 21, 2023

A study published in JAMA Oncology found that a contralateral esophagus-sparing technique reduces the risk of severe ...

Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023

Frontline tislelizumab plus chemotherapy significantly improved progression-free survival (primary endpoint) compared ...

Kerri FitzgeraldSmall Cell Lung Cancer | September 20, 2023

The U.S. Food and Drug Administration approved Imfinzi® (durvalumab) in combination with etoposide plus either ...

Kerri FitzgeraldNon-Small Cell Lung Cancer | September 20, 2023

A phase I/II study published in JAMA Oncology found that the HIV protease inhibitor Viracept® (nelfinavir mesylate) ...

Kerri FitzgeraldSmall Cell Lung Cancer | September 19, 2023

The U.S. Food and Drug Administration (FDA) approved atezolizumab in combination with carboplatin and etoposide for ...

Kaitlyn D’OnofrioLung Cancer | September 19, 2023

A recent study published in the journal Lung Cancer evaluated the effects of lung cancer nurse specialists (LCNSs) on ...

Kerri FitzgeraldLung Cancer | September 19, 2023

A study published in the journal Menopause found that among women who received chemotherapy for lung cancer ...

Kerri FitzgeraldNon-Small Cell Lung Cancer | January 24, 2020

The novel agent tislelizumab improved progression-free survival (PFS; primary endpoint) in the firstline setting in ...